Rockwell Automation Fair 2025 Event Brief Axendia participated in The Rockwell Automation Fair 2025, held in Chicago, IL. This year, the event attracted over 15,000 […]
Intelligent Autonomous Systems Fuel the Future of Industry Read More »
Insights from the 2025 Blue Mountain Summit The 2025 Blue Mountain Summit brought together industry leaders, experts, and innovators to discuss the latest trends, practices,
Blue Mountain Unveils Ambitious Product Roadmap Read More »
2025 Veeva R&D And Quality Summit Event Brief Axendia is grateful for the opportunity to once again cover the Veeva R&D and Quality Summit in Boston from
Industry Platform for Life Sciences Adds AI and Standard Applications Read More »
In 2005, Axendia was founded to meet a critical need: trusted, strategic, and actionable advice from experts who truly understand the intricate balance of business,
Axendia at 20: Forging the Future of Life Sciences! Read More »
What you need to know about the Bipartisan MAPS Act In the age of continuous disruption, from pandemics to geopolitical conflicts and trade uncertainty, the
Congress Wants to Map the Pharmaceutical Supply Chain Read More »
EQTY Lab Briefing Note Axendia was briefed by the executive team at EQTY Lab, including Dr. Tina Dr. Morrison, VP Scientific Strategy and Alistair Dootson, Head of Life
Driving AI Integrity in Life Sciences Read More »
FDA Expects That Records be Submitted in Electronic Format Nestled within FDA’s final guidance on Remote Regulatory Assessments (RRAs) is a pivotal and decisive statement:
Why Paper Won’t Cut It In FDA’s Remote Oversight Era Read More »
Insights from the 2025 Honeywell Life Sciences World Tour Axendia participated in the Honeywell Life Sciences World Tour USA. Under the theme “Innovation for a
Accelerating Innovation for a Healthier Future Read More »
The FDA is embarking on a transformative journey—one that seeks to modernize regulatory processes, accelerate approvals, and address chronic disease trends in a proactive manner.
Commissioner Unveils Priorities for a New FDA Read More »
On May 8, 2025, the U.S. Food and Drug Administration (FDA) announced a historic milestone: the completion of its first AI-assisted scientific review pilot. Additionally,
From Pilot to Policy: FDA’s AI Transformation Hits Fast Forward Read More »
On May 5, 2025, an executive order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines“ was signed by the administration. The order seeks
Strengthening Domestic Pharmaceutical Manufacturing in the Age of Continuous Disruption Read More »
Insights from Nanoprecise’s Briefing Nanoprecise leadership, including Kevin Clark, Chief Evangelist Officer, Param Desai, Chief Product Officer, and Jeffrey Hill, Director of Life Sciences, recently shared their perspective on
